Mr. Doug Wight is Vice President, Drug Development at Thryv Therapeutics. He is a seasoned scientist and drug development professional with over 35 years of experience in scientific research and drug development roles in academia, and the pharmaceutical and CRO industries.

Mr. Wight began his career in academia, conducting research in pulmonary physiology at McGill University and the Université de Montréal. He then joined the pharmaceutical industry with Sandoz (now Novartis), then moved to Searle (now Pfizer). He later joined the CRO industry with MDS Pharma Services (now Celerion) as Senior Director responsible for the strategic and operational oversight of drug development programs from discovery through clinical proof of concept for Celerion clients, including therapies for type 2 diabetes, spinal cord injury, hepatocellular carcinoma and acute bacterial infection. He moved to Milestone Pharmaceuticals in 2011, a publicly traded pharmaceutical company developing a novel therapeutic, etripamil, for treatment of Paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation, serving as VP Drug Development and lead the development of etripamil from discovery to Phase 3 clinical trials.

Mr. Wight received his BSc. in Bio-Physical Education from Concordia University and his MSc. in Physiology from McGill University.

• 

  Vice President, Drug Development in Thryv Therapeutics

  We will relentlessly pursue precision treatments targeting SGK1 to enable people to live their absolute best lives.Without Limits.